ARTICLE | Clinical News
Subcutaneous C1-INH: Phase III started
February 24, 2014 8:00 AM UTC
CSL began the double-blind, crossover, U.S. Phase III COMPACT trial to evaluate subcutaneous C1-INH twice weekly in about 80 patients with HAE types I or II who have frequent attacks. Patients will re...